Pangaea Oncology, S.A. (BME: PANG)
Spain
· Delayed Price · Currency is EUR 1.790
+0.010 (0.56%)
Nov 22, 2024, 12:00 PM CET
Pangaea Oncology Income Statement
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | 14.35 | 9.95 | 6.68 | 6.71 | 6.18 | 5.5 | Upgrade
|
| Revenue Growth (YoY) | 122.29% | 49.12% | -0.48% | 8.61% | 12.20% | -3.10% | Upgrade
|
| Cost of Revenue | 2.58 | 2.4 | 2.73 | 1.65 | 1.63 | 1.1 | Upgrade
|
| Gross Profit | 11.77 | 7.56 | 3.94 | 5.05 | 4.55 | 4.41 | Upgrade
|
| Selling, General & Admin | 13.24 | 9.35 | 5.35 | 4.41 | 3.95 | 3.92 | Upgrade
|
| Other Operating Expenses | 0.06 | -0.16 | 0.04 | 0.29 | 0.07 | 0.04 | Upgrade
|
| Operating Expenses | 15.72 | 11 | 6.64 | 5.7 | 6.43 | 7.04 | Upgrade
|
| Operating Income | -3.95 | -3.44 | -2.7 | -0.64 | -1.88 | -2.63 | Upgrade
|
| Interest Expense | -0.29 | -0.13 | -0.19 | -0.25 | -0.19 | -0.19 | Upgrade
|
| Interest & Investment Income | - | 0.12 | 0.02 | 0 | - | - | Upgrade
|
| Earnings From Equity Investments | -0.01 | -0.06 | -0.16 | -0.19 | -0.04 | - | Upgrade
|
| Currency Exchange Gain (Loss) | -0.01 | -0.01 | 0 | -0.01 | -0.02 | -0 | Upgrade
|
| Other Non Operating Income (Expenses) | 0.11 | 0.13 | 0.14 | 0.09 | 0.26 | 0.34 | Upgrade
|
| EBT Excluding Unusual Items | -4.15 | -3.39 | -2.88 | -1.01 | -1.86 | -2.49 | Upgrade
|
| Impairment of Goodwill | -0.51 | -0.51 | - | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Investments | 0.39 | 0.39 | 0.04 | -0.09 | - | - | Upgrade
|
| Asset Writedown | 0 | - | - | - | - | -2.5 | Upgrade
|
| Pretax Income | -4.27 | -3.51 | -2.84 | -1.1 | -1.86 | -4.98 | Upgrade
|
| Income Tax Expense | 1.24 | 1.29 | -0.11 | -0.46 | -0.11 | -0.14 | Upgrade
|
| Earnings From Continuing Operations | -5.51 | -4.79 | -2.72 | -0.64 | -1.75 | -4.84 | Upgrade
|
| Minority Interest in Earnings | 0.19 | 0.14 | 0.01 | - | - | - | Upgrade
|
| Net Income | -5.34 | -4.66 | -2.71 | -0.64 | -1.75 | -4.84 | Upgrade
|
| Net Income to Common | -5.34 | -4.66 | -2.71 | -0.64 | -1.75 | -4.84 | Upgrade
|
| Shares Outstanding (Basic) | 30 | 30 | 30 | 23 | 19 | 17 | Upgrade
|
| Shares Outstanding (Diluted) | 30 | 30 | 30 | 23 | 19 | 17 | Upgrade
|
| Shares Change (YoY) | 3.35% | -0.98% | 35.11% | 20.34% | 10.89% | 28.80% | Upgrade
|
| EPS (Basic) | -0.18 | -0.15 | -0.09 | -0.03 | -0.09 | -0.29 | Upgrade
|
| EPS (Diluted) | -0.18 | -0.15 | -0.09 | -0.03 | -0.09 | -0.29 | Upgrade
|
| Free Cash Flow | -2.9 | -2.65 | -3.7 | -2.53 | -1.99 | -2.4 | Upgrade
|
| Free Cash Flow Per Share | -0.10 | -0.09 | -0.12 | -0.11 | -0.11 | -0.14 | Upgrade
|
| Gross Margin | 82.01% | 75.92% | 59.06% | 75.36% | 73.63% | 80.09% | Upgrade
|
| Operating Margin | -27.52% | -34.59% | -40.40% | -9.56% | -30.51% | -47.86% | Upgrade
|
| Profit Margin | -37.18% | -46.78% | -40.63% | -9.57% | -28.37% | -87.93% | Upgrade
|
| Free Cash Flow Margin | -20.19% | -26.66% | -55.36% | -37.67% | -32.16% | -43.56% | Upgrade
|
| EBITDA | -3.26 | -2.69 | -2.31 | -0.27 | -1.51 | -2.2 | Upgrade
|
| EBITDA Margin | -22.70% | -27.07% | -34.62% | -4.02% | -24.38% | -39.92% | Upgrade
|
| D&A For EBITDA | 0.69 | 0.75 | 0.39 | 0.37 | 0.38 | 0.44 | Upgrade
|
| EBIT | -3.95 | -3.44 | -2.7 | -0.64 | -1.88 | -2.63 | Upgrade
|
| EBIT Margin | -27.52% | -34.59% | -40.40% | -9.56% | -30.51% | -47.86% | Upgrade
|
| Revenue as Reported | 12.26 | 8 | 4.37 | - | - | - | Upgrade
|
| Advertising Expenses | - | 0.18 | 0.07 | 0.03 | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.